What is the primary purpose of ICH-GCP Guideline E6?

What is the primary purpose of ICH-GCP Guideline E6?

• A. To protect the rights, safety, and well-being of trial participants and ensure the integrity of trial data.
• B. To accelerate trial timelines and reduce regulatory oversight.
• C. To standardize labeling of investigational products only.
• D. To maximize sponsor profitability during trials.

Answer: (A)

ICH-GCP E6 sets international standards for ethically and scientifically sound conduct of clinical trials involving humans. Its primary purpose is to protect the rights, safety, and well-being of trial participants and to ensure the integrity and credibility of the trial data. This means obtaining proper informed consent, minimizing risks, monitoring safety, and ensuring that trial data are accurate, complete, and verifiable. It also defines responsibilities for sponsors, investigators, and ethics committees to maintain rigorous documentation and quality assurance throughout the study. The guideline is not about speeding up timelines or reducing oversight, nor is it limited to labeling or sponsor profitability; its core aim is to uphold participant protection and reliable data so that regulatory authorities can trust the trial results.

ICH-GCP E6 sets international standards for ethically and scientifically sound conduct of clinical trials involving humans. Its primary purpose is to protect the rights, safety, and well-being of trial participants and to ensure the integrity and credibility of the trial data. This means obtaining proper informed consent, minimizing risks, monitoring safety, and ensuring that trial data are accurate, complete, and verifiable. It also defines responsibilities for sponsors, investigators, and ethics committees to maintain rigorous documentation and quality assurance throughout the study. The guideline is not about speeding up timelines or reducing oversight, nor is it limited to labeling or sponsor profitability; its core aim is to uphold participant protection and reliable data so that regulatory authorities can trust the trial results.